PAR2

PAR2 Molekülinformation

Englischer Name	Protease-activated receptor-2	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3	Target-Alias	Receptor， PAR-2，F2RL1，Thrombin receptor-like 1，G-protein coupled receptor 11，F2R Like Trypsin Receptor 1，PAR2，GPR11，Protease-Activated Receptor 2，Coagulation Factor II (Thrombin) Receptor-Like 1，Proteinase-Activated Receptor-2，Proteinase-activated receptor 2，Coagulation factor II receptor-like 1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Protease-activated receptor-2
Target-Alias	Receptor， PAR-2，F2RL1，Thrombin receptor-like 1，G-protein coupled receptor 11，F2R Like Trypsin Receptor 1，PAR2，GPR11，Protease-Activated Receptor 2，Coagulation Factor II (Thrombin) Receptor-Like 1，Proteinase-Activated Receptor-2，Proteinase-activated receptor 2，Coagulation factor II receptor-like 1
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

PAR2 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
- (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
PA2-H52P7	Human	HEK293	Human PAR2 Full Length Protein (VLP)				In den Warenkorb legen

Gesamtmenge1

PAR2 Molekülhintergrund

This gene encodes a member of the G-protein coupled receptor 1 family of proteins. The encoded cell surface receptor is activated through proteolytic cleavage of its extracellular amino terminus, resulting in a new amino terminus that acts as a tethered ligand that binds to an extracellular loop domain. Activation of the receptor has been shown to stimulate vascular smooth muscle relaxation, dilate blood vessels, increase blood flow, and lower blood pressure. This protein is also important in the inflammatory response, as well as innate and adaptive immunity. [provided by RefSeq, Jun 2016]

PAR2 Molekülalias

PAR2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
MEDI-0618	MEDI-0618; MEDI0618; ABBV-2002; ABBV2002	Phase 2 Clinical	Astrazeneca Plc	Chronic Pain; Migraine Disorders	Details
TEV-56192	TEV-56192	Phase 1 Clinical	Teva Pharmaceutical Industries Ltd	Nervous System Diseases	Details
OA-235i	OA-235i	Phase 1 Clinical	Oasis Pharmaceuticals LLC	Metabolic Dysfunction-Associated Steatotic Liver Disease	Details